Sign in
Taking peoplePhase 3

Evaluation of early administration of Levetiracetam in the prevention and treatment of delirium during septic shock: a randomized, double-blind, placebo-controlled trial. KiSS

Key facts

Who runs it
Assistance Publique Hopitaux De Paris
Where
France11 sites in 1 countryChoose a country to see its sites
Status
Recruiting
Phase
Phase 3
People taking part
280 people, planned
Started
31 Jul 2025
Expected to end
2 Apr 2027
Type of study
Interventional
Record updated
28 September 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • age ≥18 years
  • hospitalized in intensive care for less than 96 hours with septic shock evolving for less than 24 hours, defined by : o a clinically or microbiologically documented infection and o a SOFA score ≥2 or an increase in SOFA ≥2 points if organ dysfunction was present prior to infection and o the need for vasopressor administration to maintain a mean arterial pressure ≥65mmHg and o lactatemia > 2mmol/L (18mg/dL) despite adequate vascular filling
  • consent of patient, family member or inclusion in emergency situation without prior consent of patient or family member

Who cannot take part

  • Patients in a situation where active therapies are limited, or for whom the therapeutic commitment is not maximal
  • Patients with limitations on life-sustaining therapies or for whom therapeutic commitment is not maximal
  • Concomitant treatment with Methotrexate during the administration of the investigational treatment
  • Patientswho Participate in another interventional trial with a drug that could interact with levetiracetam or have an impact on the evaluation of the KiSS trial endpoints. In case of doubt, please contact the trial coordinating investigator
  • Chronic long-term antiepileptic treatment upon admission or patient with uncontrolled seizures
  • Patients with Chronic or progressive central neurological pathologies of traumatic, inflammatory, vascular, infectious, neoplastic or degenerative origin, defined by cognitive impairment not allowing independent living or an IQCODE score > 4.5
  • Patients with Allergy to levetiracetam
  • Patient with moderate to severe dementia
  • Patients presenting with signs of depression and/or suicidal ideation or suicidal behavior and/or a history of suicide attempt(s)
  • Patient With a prolonged QTc interval on ECG and/or any of the high arrhythmic-risk cardiovascular conditions defined below: • Congenital or acquired long QT syndrome (QTc ≥ 470 ms in males, ≥ 480 ms in females) or a history of torsades de pointes; • Documented history of sustained ventricular tachycardia, ventricular fibrillation, or arrhythmia-related cardiac arrest; • Inherited cardiac disease associated with a high risk of arrhythmia (including arrhythmogenic right ventricular cardiomyopathy, Brugada syndrome, and channelopathies); • Severe unstable heart failure (unstable NYHA class III–IV or recent decompensation)
  • Patients with Severe head injury less than 3 months old
  • Minor patients
  • Patients with Pregnancy in progress (bHCG blood or urine)
  • Chronic or progressive central neurological pathologies of traumatic, inflammatory, vascular, infectious, neoplastic, or degenerative origin, defined by cognitive impairments preventing independent living or an IQCODE score > 4.5
  • Severe head trauma within the past 3 months
  • Nursing mothers
  • Patient under guardianship or trusteeship
  • Patients Not affiliated to a social security scheme or CMU

This trial is currently available in France.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To assess the impact of early 7-day administration of levetiracetam in patients with septic shock hospitalized in the ICU on the number of days alive without coma or delirium at D14.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
28 September 2026